Analgin Reneval, tablets 500 mg 20 pcs
€5.99 €5.32
ATX: N.02.B.B.02 Sodium Metamizole
Pharmacodynamics:
Sodium Metamizole is a non-narcotic analgesic, pyrazolone derivative, non-seliquely blocks cyclooxygenase and reduces prostaglandin formation from arachidonic acid.
Inhibits conduction of pain extra- and proprioreceptive impulses along the Goll and Bourdach bundles, increases threshold of excitability of thalamic centers of pain sensitivity, increases heat release.
The distinctive feature is the slight anti-inflammatory effect, causing a weak effect on the water-salt metabolism (retention of sodium and water ions) and the mucous membrane of the gastrointestinal tract. It has analgesic, antipyretic and some antispasmodic (against the smooth muscle of the urinary and biliary tracts) effects. The action develops 20-40 minutes after taking the drug and reaches a maximum in 2 hours.
Maximum plasma concentration is reached 1-1.5 h after oral administration. In the intestinal wall it is hydrolyzed to form the active metabolite. There is no unchanged sodium metamizole in blood. The binding of the active metabolite to proteins is 50-60%. Excretion of metabolites is via the kidneys. In addition, metabolites are excreted with breast milk.
.
Indications
Fever syndrome in infectious and inflammatory diseases, insect bites, post-transfusion complications.
Pain syndrome (mild to moderate intensity): including neuralgia, myalgia, biliary colic, renal colic, postoperative pain syndrome, headache, toothache, algodysmenorrhea.
Active ingredient
Composition
Active ingredient:
Metamizole sodium – 0,5 g,
Excipients:
potato starch – 0.0334 g,
sucrose (sugar) – 0.0055 g,
Calcium stearate – 0,0028 g,
stearic acid – 0,0028 g,
talcum – 0,0055 g.
How to take, the dosage
Ingestion.
The maximum single dose is 1 g, the daily dose is 3 g.
For children from 8 years to 14 years the recommended dose is 250 mg, for children from 15 years and adults – 250-500 mg, the frequency of use is 2-3 times a day.
The duration of use without consulting a doctor is not more than 5 days.
Interaction
Rentgen contrast agents, colloidal blood substitutes and penicillin should not be used during treatment with sodium metamizole. Concomitant use of cyclosporine decreases the concentration of the latter in blood.
Phenylbutazone, barbiturates and other inducers of microsomal liver enzymes decrease the effectiveness of sodium metamizole when used concomitantly.
Simultaneous use with other non-narcotic analgesics, tricyclic antidepressants, contraceptive hormonal drugs and allopurinol may lead to increased toxicity.
Sodium metamizole increases the effects of ethanol; concomitant use with chlorpromazine or phenothiazine may lead to marked hyperthermia.
Sedative and anxiolytic drugs (tranquilizers) increase the analgesic effects of sodium metamizole
Thiamazole and cytostatics increase the risk of leukopenia.
The effect is enhanced by codeine, H2-histamine receptor blockers and propranololol (slows inactivation).
Myelotoxic drugs increase manifestations of hematotoxicity of the drug.
Special Instructions
When treating patients receiving cytostatic drugs, administration of sodium metamizole should be carried out only under medical supervision.
Patients with atopic bronchial asthma and pollinosis have an increased risk of allergic reactions.
In patients taking sodium metamizole, agranulocytosis may develop, therefore, if unexplained fever, chills, sore throat, difficulty swallowing, stomatitis, and if vaginitis or proctitis occur, the drug should be stopped immediately.
The peripheral blood count should be monitored with long-term use.
The drug should not be used for acute abdominal pain (until the cause is known).
Contraindications
Hypersensitivity to the components of the drug, suppression of hematopoiesis (agranulocytosis, cytostatic or infectious neutropenia), hepatic and/or renal failure, hereditary hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency, sucrose/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption, bronchial asthma induced by taking acetylsalicylic acid, salicylates or other nonsteroidal anti-inflammatory drugs, anemia, leukopenia, pregnancy, lactation, age under 8 years.
Renal diseases (pyelonephritis, glomerulonephritis, including in anamnesis), alcoholism, predisposition to develop arterial hypotension.
Side effects
Urinary system disorders: impaired renal function, oliguria, anuria, proteinuria, interstitial nephritis, red staining of urine.
Allergic reactions: urticaria (including conjunctivitis and mucous membranes of the nasopharynx), angioedema, erythema malignant exudative (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell syndrome), bronchospastic syndrome, anaphylactic shock.
Hematopoietic disorders: agranulocytosis, leukopenia, thrombocytopenia.
Others: decreased blood pressure.
Overdose
Symptoms: nausea, vomiting, epigastric pain, oliguria, hypothermia, decreased blood pressure, tachycardia, shortness of breath, tinnitus, drowsiness, delirium, impaired consciousness, acute agranulocytosis, hemorrhagic syndrome, acute renal and/or liver failure, seizures, paralysis of respiratory muscles.
Treatment: gastric lavage, saline laxatives, activated charcoal; performing forced diuresis, hemodialysis, in case of convulsive syndrome – intravenous diazepam and quick-acting barbiturates.
Pregnancy use
Similarities
Weight | 0.020 kg |
---|---|
Shelf life | 5 years. Do not use after the expiration date. |
Conditions of storage | In the dark place at a temperature not exceeding 25 °С. Store out of the reach of children. |
Manufacturer | Update PFC AO, Russia |
Medication form | pills |
Brand | Update PFC AO |
Related products
Buy Analgin Reneval, tablets 500 mg 20 pcs with delivery to USA, UK, Europe and over 120 other countries.